Does Sharp Health Plan Cover Prolia?

What Is Prolia and Why Is It Prescribed?

Prolia is the brand name for denosumab, a fully human monoclonal antibody that inhibits RANK ligand, the key signal that activates bone-resorbing osteoclasts. By blocking RANK ligand, denosumab reduces bone turnover and increases bone mineral density (BMD). The FDA approved Prolia in June 2010 for postmenopausal women with osteoporosis at high fracture risk, later expanding the label to include men with osteoporosis, patients on long-term glucocorticoids, and individuals losing bone as a result of androgen-deprivation or aromatase-inhibitor therapy [1].

The FREEDOM trial (N=7,868) demonstrated that 60 mg denosumab given subcutaneously every six months reduced new vertebral fracture risk by 68%, hip fracture risk by 40%, and nonvertebral fracture risk by 20% over 36 months compared with placebo [2]. These data underpin guideline recommendations from the American Association of Clinical Endocrinology (AACE), which lists denosumab as a preferred agent for high-fracture-risk patients who cannot tolerate or have not responded to oral bisphosphonates [3].

Because Prolia costs roughly $1,350, $1,500 per injection without insurance, most health plans, including Sharp Health Plan, require prior authorization (PA) before they will pay for it.

How Sharp Health Plan Generally Handles Prolia Coverage

Sharp Health Plan is a San Diego-based, not-for-profit HMO and PPO that uses a tiered drug formulary reviewed and updated periodically. Specialty biologics such as Prolia typically land in a high-cost specialty tier or are processed as a medical benefit (administered in a physician's office and billed on a medical claim rather than a pharmacy claim).

Placement matters for cost-sharing. When billed as a medical benefit, members pay a specialist office-visit copay plus a percentage of the drug's allowed amount rather than a fixed specialty-tier copay. Members should confirm with Sharp's Member Services (1-800-359-2002) exactly which benefit bucket applies to their specific plan, because HMO and PPO cost-sharing structures differ.

Prior authorization is standard. Sharp Health Plan, like the majority of California commercial plans, requires PA for Prolia to verify medical necessity before coverage is extended. The National Osteoporosis Foundation (now Bone Health and Osteoporosis Foundation, BHOF) defines high fracture risk as a T-score of -2.5 or lower, or a T-score between -1.0 and -2.5 with a FRAX 10-year probability of 20% or higher for major osteoporotic fracture or 3% or higher for hip fracture [4].

Prescribers should submit PA requests with the following documentation:

• A recent DXA scan report (within the past 24 months) showing T-scores and the facility that performed the scan
• The patient's FRAX score or documented fracture history
• Diagnosis codes (M81.0 for postmenopausal osteoporosis; M80.00 for age-related osteoporosis with pathological fracture, if applicable)
• Clinical rationale if step therapy is being waived (see below)

Step Therapy Requirements: What Comes Before Prolia?

Many insurers, including California HMOs, apply step therapy protocols that require patients to try less expensive alternatives first. For osteoporosis, that typically means an oral bisphosphonate, most often alendronate (Fosamax) or risedronate (Actonel).

Alendronate 70 mg once weekly has been shown in the Fracture Intervention Trial (FIT, N=2,027) to reduce vertebral fracture risk by 47% and hip fracture risk by 51% over 36 months in women with prior vertebral fracture [5]. Because generic alendronate costs as little as $4, $10 per month, most plans treat it as the first-line agent.

Step therapy can typically be bypassed if the prescriber documents one of these clinical situations:

1. A contraindication to bisphosphonates (creatinine clearance <35 mL/min per alendronate's prescribing information; active or recent esophageal disease; inability to remain upright for 30 minutes)
2. A documented intolerance or adverse event during prior bisphosphonate use (esophagitis, severe musculoskeletal pain, atypical femur fracture)
3. A prior bisphosphonate trial of at least 12 months with continued fracture or ongoing significant bone loss on serial DXA
4. A very high fracture-risk scenario (T-score <-3.0, multiple prior fragility fractures, or glucocorticoid use of prednisone 7.5 mg/day or more for longer than 3 months) where the AACE 2020 guidelines recommend starting with an anabolic or potent antiresorptive agent [3]

California's SB 1083, signed into law in 2018, limits step therapy for certain conditions and grants expedited exceptions when a physician certifies that the required drug is contraindicated or clinically inappropriate. Prescribers who believe the step-therapy requirement puts a patient at risk should cite this statute when requesting an exception [6].

Prior Authorization Criteria: What the Prescriber Must Prove

Sharp Health Plan's PA criteria for Prolia (denosumab) are grounded in FDA label indications and major guideline thresholds. Although Sharp does not publish its full PA criteria publicly, the criteria used by California HMOs typically align with the following evidence-based thresholds.

For postmenopausal osteoporosis: A DXA T-score of -2.5 or lower at the lumbar spine, femoral neck, or total hip; or a T-score between -1.0 and -2.5 combined with a prior low-trauma fracture after age 50; or a FRAX 10-year major fracture probability of 20% or higher [4].

For male osteoporosis: FDA approval covers men at high fracture risk. The Endocrine Society's 2012 clinical practice guideline on male osteoporosis supports pharmacological treatment when the T-score is -2.5 or lower or when FRAX thresholds are met [7].

For glucocorticoid-induced osteoporosis (GIOP): The American College of Rheumatology 2022 GIOP guideline conditionally recommends denosumab for high-risk patients on glucocorticoids, particularly when renal function precludes bisphosphonate use [8]. Prednisone-equivalent doses of 7.5 mg/day or more for three months or longer, combined with a T-score below -1.5 or a prior fracture, generally meet medical-necessity thresholds.

For oncology-related bone loss: Denosumab is covered under the Xgeva brand (120 mg, different dose and indication) for skeletal-related events in solid tumor metastases. That is a separate coverage pathway from Prolia's osteoporosis indication. Prescribers must ensure they are requesting the correct drug, dose, and indication to avoid automatic denial.

The prescriber's office submits the PA request through Sharp's provider portal or by fax to the Medical Management department. Routine PA decisions are rendered within 3, 5 business days; urgent or expedited requests must be decided within 72 hours under California law (Health and Safety Code Section 1367.01) [9].

What Happens If Sharp Health Plan Denies Prolia Coverage?

A denial is not necessarily final. Federal and California law give members several appeal pathways.

Internal appeal. The member or prescriber requests a reconsideration review within 60 days of the denial. Sharp must respond within 30 days (standard) or 72 hours (expedited, if the member's health would be seriously jeopardized by delay). The prescribing physician should submit a letter of medical necessity that addresses the specific denial reason, references peer-reviewed literature such as the FREEDOM trial [2], and cites the relevant guideline recommendation [3].

Independent Medical Review (IMR). If the internal appeal is denied, California members may request an IMR through the Department of Managed Health Care (DMHC) at no cost. The IMR is conducted by an independent organization contracted by the state. Data from the DMHC show that IMR outcomes overturn insurer denials at rates that vary by drug class, underscoring the value of submitting a well-documented appeal [10].

Expedited IMR. When a standard timeline poses imminent risk to the patient (for example, a patient with multiple recent fragility fractures), the DMHC can expedite the review to 3 business days.

State complaint. Members may also file a complaint with the DMHC Help Center (1-888-466-2219) if they believe the denial violates California's step-therapy exception law or the plan's own evidence-based coverage criteria.

The HealthRX clinical team recommends that prescribers use the following documentation framework when appealing a Prolia denial:

1. State the patient's T-score, site measured, and DXA facility.
2. State the FRAX 10-year probability and confirm the FRAX version used.
3. Document the bisphosphonate trial (drug, dose, duration, outcome) or the contraindication with supporting lab values (e.g., eGFR <35 mL/min).
4. Quote the AACE 2020 guideline recommendation level and grade for denosumab in the patient's risk category [3].
5. Reference the FREEDOM trial 68% vertebral fracture risk reduction for high-risk patients [2].
6. Request an expedited decision if the patient has had a fragility fracture within the preceding 12 months.

Cost-Sharing, Copays, and Patient Assistance

Even when Prolia is approved, the member's out-of-pocket cost depends on the plan design. Sharp HMO plans sold through Covered California may have different cost-sharing from employer-sponsored Sharp PPO plans. Members should ask Sharp Member Services for the allowed amount for HCPCS code J0897 (denosumab injection, 1 mg) and their applicable coinsurance percentage.

Amgen's Prolia Assist program can reduce out-of-pocket costs to $0 per dose for eligible commercially insured patients who meet income criteria. The program is administered through Amgen's patient support line (1-800-772-6436). Medicare and Medicaid beneficiaries are not eligible for manufacturer copay cards under federal anti-kickback provisions, but the Prolia Assist program does offer a separate Medicare Part D gap coverage option for qualifying patients [11].

Specialty pharmacy copay maximums. Some Sharp employer-sponsored plans cap specialty drug cost-sharing at $150, $250 per fill under the plan's specialty tier, which can meaningfully reduce annual out-of-pocket spending on two injections per year.

Medicare Advantage through Sharp. Sharp offers Medicare Advantage plans in San Diego County. Prolia billed under the medical benefit (Part B) typically carries an 80/20 cost-sharing structure after the Part B deductible ($240 in 2024). Prolia dispensed through Part D (retail pharmacy) would apply toward the redesigned Part D out-of-pocket maximum of $2 to 000 in 2025 under the Inflation Reduction Act's drug-pricing provisions.

Clinical Context: Why Treating Osteoporosis Promptly Matters

Osteoporosis is not a cosmetic concern. The CDC estimates that approximately 10 million Americans have osteoporosis and another 44 million have low bone mass (osteopenia), placing them at elevated fracture risk [12]. Hip fractures carry a one-year mortality rate of approximately 20 to 24% in adults over 65 [13]. The Surgeon General's 2004 report on bone health established that osteoporosis-related fractures cost the U.S. healthcare system more than $17 billion annually [14].

Delayed treatment increases fracture risk. Each year of treatment delay in a patient with a T-score of -2.5 or lower and a prior vertebral fracture represents a clinically meaningful window of preventable harm. The AACE 2020 guidelines state: "For patients at very high fracture risk, pharmacological therapy should be initiated without delay, using agents with the strongest evidence for fracture reduction" [3]. Denosumab meets that criterion based on FREEDOM data [2].

Discontinuation risk is also worth flagging. Unlike bisphosphonates, which bind to bone mineral and continue to exert antiresorptive effects after discontinuation, denosumab's effect reverses rapidly when injections are stopped. The FREEDOM Extension study showed that patients who discontinued denosumab experienced rapid increases in bone turnover markers and multiple vertebral fractures within 12 to 24 months of the last injection [15]. This means coverage gaps due to PA delays or administrative denials carry real clinical consequences. Prescribers should start the PA process no later than 60 days before the next scheduled injection.

Alternatives If Prolia Is Not Covered

If Sharp Health Plan denies Prolia and an appeal is unsuccessful, the prescriber has several evidence-based alternatives to consider.

Zoledronic acid (Reclast) 5 mg IV annually. The HORIZON-PFT trial (N=7,765) showed a 70% reduction in morphometric vertebral fractures over 36 months [16]. Zoledronic acid is a generic drug and may have more favorable formulary placement. It also bypasses GI absorption concerns that complicate oral bisphosphonate use.

Romosozumab (Evenity) 210 mg SC monthly for 12 months. The ARCH trial (N=4,093) showed romosozumab followed by alendronate reduced vertebral fracture risk by 48% and hip fracture risk by 38% compared with alendronate alone [17]. Romosozumab carries an FDA boxed warning for major adverse cardiovascular events and is reserved for very high-risk patients without recent MI or stroke [18].

Teriparatide (Forteo) 20 mcg SC daily for up to 24 months. The key fracture prevention trial (N=1,637) demonstrated a 65% reduction in new vertebral fractures versus placebo [19]. Teriparatide is an anabolic agent appropriate for severe or glucocorticoid-induced osteoporosis but carries a cost similar to or higher than Prolia.

Abaloparatide (Tymlos) 80 mcg SC daily. The ACTIVE trial (N=2,463) showed an 86% reduction in new vertebral fractures versus placebo at 18 months [20]. Like teriparatide, abaloparatide is limited to 24 months of cumulative use.

Each of these alternatives requires its own PA process and documentation. The prescriber's choice should be guided by the patient's renal function, cardiovascular history, fracture severity, and ability to administer self-injection.

How to Confirm Your Specific Sharp Health Plan Prolia Coverage

Coverage rules change with each plan year and benefit design. Members should take three concrete steps before assuming coverage:

First, call Sharp Member Services at 1-800-359-2002 and ask specifically whether denosumab (Prolia) is covered under the medical or pharmacy benefit for your plan ID, what the applicable cost-sharing percentage is, and whether a prior authorization is required.

Second, ask your prescribing provider's office to run a benefits verification through Sharp's provider portal before scheduling the injection. Many rheumatology, endocrinology, and gynecology practices that routinely prescribe Prolia employ staff who handle this verification daily.

Third, request a written Summary of Benefits and Coverage (SBC) document for your plan year. Under the ACA, this document must state cost-sharing for specialty drugs and biologics and must be provided free of charge within seven business days of request. Reviewing the SBC alongside Sharp's drug formulary (available at sharp.com) gives you the most accurate picture of what you will owe at the time of service.